News/ News/ R&D Chord gets $16m to challenge Alexion with oral NMOSD drug Phil Taylor Chord Therapeutics, financing, NMOSD, rare disease, switzerland 0 Comment Swiss biotech Chord Therapeutics has come out of stealth mode with a $16 million first-round financing that will Share X Chord gets $16m to challenge Alexion with oral NMOSD drug https://pharmaphorum.com/news/chord-gets-16m-to-challenge-alexion-with-oral-nmosd-drug/
News/ News/ Sales and Marketing Roche takes on Alexion as FDA approves satralizumab in NMOSD Richard Staines Alexion, inflammatory diseases, neurology, NMOSD, Roche 0 Comment The FDA has approved Roche’s satralizumab for the rare autoimmune disorder Neuromyelitis Optica Spectrum Disorder (NMOSD), under the Share X Roche takes on Alexion as FDA approves satralizumab in NMOSD https://pharmaphorum.com/news/roche-takes-on-alexion-as-fda-approves-satralizumab-in-nmosd/
Chord Therapeutics, financing, NMOSD, rare disease, switzerland
0 Comment
